The study aims to evaluate the effectiveness and safety of a collaborative nurse-allergist approach in penicillin allergy delabeling services. It also seeks to assess the impact on patients' quality of life and compare resource utilization and cost-effectiveness between the nurse-allergist collaborative approach and the traditional allergist-led approach.
This study hypothesizes that by involving both nurses and allergists in the delabeling process and categorizing patients based on risk levels, it will achieve comparable success rates, safety, and improvements in patients' quality of life. This approach is expected to offer superior advantages in terms of time efficiency, resource utilization, and cost-effectiveness compared to traditional allergist-led services.
Study Type
OBSERVATIONAL
Enrollment
440
Patients in this group undergo risk assessment and categorization by nurses to identify low-risk individuals for delabeling. For these patients, nurses will collaborate with allergists in the delabeling process.
Patients assigned to this group will undergo risk assessment and delabeling led by allergists for both low-risk and high-risk cases.
Prince of Wales Hospital
Hong Kong, Hong Kong
RECRUITINGPrincess Margaret Hospital
Hong Kong, Hong Kong
RECRUITINGQueen Elizabeth Hospital
Hong Kong, Hong Kong
RECRUITINGDelabelling Success Rate
Assess the proportion of low-risk patients who are no longer considered allergic to penicillin after delabeling.
Time frame: 6 months
Health-Related Quality of Life
Measure changes in patients' quality of life before and after delabeling using the validated Drug Hypersensitivity Quality of Life Questionnaire (DrHy-Q). The DrHy-Q is a 15-item instrument answered on a 5-point Likert scale, with scores ranging from 15 (no QoL impairment) to 225 (worst QoL impairment).
Time frame: 6 months
Antibiotic Usage Rate
Evaluate changes in the usage rates of penicillin and alternative antibiotics after delabeling.
Time frame: 6 months
Age Group Analysis
Compare delabeling success rates across different age groups (e.g., 18-30 years, 31-50 years, and 51 years and older).
Time frame: 6 months
Immunocompetence Status
Analyze differences in delabeling success rates and safety between immunocompetent and immunocompromised patients.
Time frame: 6 months
Initial vs. Recurrent Labeling
Compare delabeling success rates between patients with an initial penicillin allergy label and those with recurrent labels.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Queen Mary Hospital
Hong Kong, Hong Kong
RECRUITING